Sandbox/00015

Jump to navigation Jump to search



Pathogen-Based Therapy — Bacteria Adapted from Lancet. 2010;375(9717):846-55.[1] and Clin Microbiol Rev. 2002;15(4):527-44.[2]

▸ Click on the following categories to expand treatment regimens.

Bacteria

  ▸  Bacteroides fragilis

  ▸  Brucella melitensis

  ▸  Enterococcus spp.

  ▸  Escherichia coli

  ▸  Haemophilus influenzae

  ▸  Morganella morganii

  ▸  Neisseria gonorrhoeae

  ▸  Proteus mirabilis

  ▸  Proteus vulgaris, Proteus rettgeri

  ▸  Pseudomonas aeruginosa

  ▸  Serratia marcescens

  ▸  Staphylococcus aureus

  ▸  Staphylococcus epidermidis

  ▸  Streptococcus agalactiae

  ▸  Streptococcus pyogenes

  ▸  Tropheryma whipplei

Mycobacteria

  ▸  Mycobacterium tuberculosis

Spirochetes

  ▸  Borrelia burgdorferi

  ▸  Treponema pallidum

Bacteroides fragilis
Preferred Regimen
Clindamycin 900 mg IV/IM q8h
OR
Metronidazole 500 mg IV q8h
Alternative Regimen
Ampicillin-Sulbactam 3 g IV q6h
OR
Ticarcillin-Clavulanate 3.1 g IV q4–6h
Morganella morganii
Preferred Regimen
Cefotaxime 2 g IV q6h
OR
Imipenem 500 mg IV q6h
OR
Levofloxacin 500 mg IV/PO q24h
Alternative Regimen
Gentamicin 3–5 mg/kg/day IV q6–8h
OR
Ticarcillin-Clavulanate 3.1 g IV q4–6h
Proteus vulgaris, Proteus rettgeri
Preferred Regimen
Cefotaxime 2 g IV q6h
OR
Imipenem 500 mg IV q6h
OR
Levofloxacin 500 mg IV/PO q24h
Alternative Regimen
Gentamicin 3–5 mg/kg/day IV q6–8h
OR
Ticarcillin-Clavulanate 3.1 g IV q4–6h
Serratia marcescens
Preferred Regimen
Cefotaxime 2 g IV q6h
Alternative Regimen
Levofloxacin 500 mg IV/PO q24h
OR
Gentamicin 3–5 mg/kg/day IV q6–8h
OR
Imipenem 500 mg IV q6h
Brucella melitensis
Preferred Regimen
Doxycycline 100 mg PO bid for ≥6 weeks
PLUS
Streptomycin 15 mg/kg IM qd for 2–3 weeks
OR
Rifampin 600–900 mg qd for ≥6 weeks
Alternative Regimen
Doxycycline 100 mg PO bid for ≥6 weeks
PLUS
Gentamicin 5 mg/kg IV qd for 7 days
Adapted from PLoS Med. 2007;4(12):e317.[3] and Lancet Infect Dis. 2007;7(12):775-86.[4] and Cochrane Database Syst Rev. 2012;10:CD007179.[5]
Methicillin-Sensitive S. aureus
Preferred Regimen
Nafcillin 2 g IV q6h
OR
Clindamycin 900 mg IV q8h
Alternative Regimen
Cefazolin 0.25–1 g IV/IM q6–8h
OR
Vancomycin 500 mg IV q6h (or 1 g IV q12h)
Methicillin-Resistant S. aureus (Adult)
Preferred Regimen
Vancomycin 15–20 mg/kg IV q8–12h
OR
Daptomycin 6 mg/kg IV q24h
OR
Linezolid 600 mg PO/IV q12h
Alternative Regimen 1
TMP-SMX 3.5–4.0 mg/kg PO/IV q8–12h (TMP component)
PLUS
Rifampin 300–600 mg PO/IV q12h
Alternative Regimen 2
Clindamycin 600 mg IV/IM q8h
Methicillin-Resistant S. aureus (Pediatric)
Preferred Regimen
Vancomycin 15 mg/kg IV q6h
OR
Clindamycin 10 mg/kg PO/IV q6h (or 13 mg/kg PO/IV q8h)
Alternative Regimen
Daptomycin 6–10 mg/kg IV q24h
OR
Linezolid 10 mg/kg PO/IV q8h (Maximum: 600 mg/dose)
Adapted from Clin Infect Dis. 2011;52(3):e18-55.[6]
Methicillin-Sensitive S. epidermidis
Preferred Regimen
Nafcillin 2 g IV q6h
OR
Clindamycin 900 mg IV/IM q8h
Alternative Regimen
Cefazolin 0.25–1 g IV/IM q6–8h
OR
Vancomycin 500 mg IV q6h (or 1 g IV q12h)
Methicillin-Resistant S. epidermidis
Preferred Regimen
Vancomycin 500 mg IV q6h (or 1 g IV q12h)
OR
Linezolid 600 mg IV q12h
Alternative Regimen 1
TMP-SMX 3.5–4.0 mg/kg PO/IV q8–12h (TMP component)
OR
Minocycline 200 mg PO x 1 dose, then 100 mg PO q12h
PLUS
Rifampin 300–600 mg PO/IV q12h
Alternative Regimen 2
Clindamycin 900 mg IV/IM q8h
Streptococcus agalactiae
Preferred Regimen
Penicillin G 2 MU IV/IM q4h
OR
Ampicillin 2 g IV q6h
Alternative Regimen
Clindamycin 600–1200 mg/day IV/IM q6–12h
OR
Cefazolin 0.25–1 g IV/IM q6–8h
Streptococcus pyogenes
Preferred Regimen
Penicillin G 2 MU IV/IM q4h
OR
Ampicillin 2 g IV q6h
Alternative Regimen
Clindamycin 600–1200 mg/day IV/IM q6–12h
OR
Cefazolin 0.25–1 g IV/IM q6–8h
Escherichia coli
Preferred Regimen
Ampicillin-Sulbactam 3 g IV q6h
Alternative Regimen
Cefazolin 0.25–1 g IV/IM q6–8h
OR
Levofloxacin 500–750 mg IV/PO q24h
OR
Gentamicin 3–5 mg/kg/day IV q6–8h
OR
TMP-SMX 8–10 mg/kg/day IV/PO q6–12h (TMP component)
Pseudomonas aeruginosa
Preferred Regimen
Cefepime 2 g IV q12h
OR
Piperacillin 3–4 g IV q4–6h
OR
Imipenem 500 mg IV q6h
Alternative Regimen
Ticarcillin-Clavulanate 3.1 g IV q4–6h
OR
Tobramycin 3-5 mg/kg/day IV q6–8h
OR
Amikacin 15 mg/kg/day IV/IM q8–12h
OR
Ciprofloxacin 400 mg IV q8–12h
Neisseria gonorrhoeae
Preferred Regimen
Ceftriaxone 2 g IV q24h
OR
Cefotaxime 1 g IV q8h
Alternative Regimen
Levofloxacin 500 mg IV/PO q24h
OR
Ampicillin 2 g IV q6h
Haemophilus influenzae
Preferred Regimen
Amoxicillin-clavulanate 875/125 mg PO q12h
OR
Cefprozil 500 mg PO q12h
OR
Cefuroxime 500 mg PO q12h
OR
Cefdinir 600 mg PO q24h
Alternative Regimen
Levofloxacin 750 mg IV/PO q24h
OR
Moxifloxacin 400 mg IV/PO q24h
OR
Clarithromycin 500 mg PO q12h
Mycobacterium tuberculosis
Intensive Phase
Isoniazid 5mg/kg PO q24h for 2 months
OR
Isoniazid 10 mg/kg PO 3 times per week × 2 months
PLUS
Rifampicin 10 mg/kg PO q24h for 2 months
OR
Rifampicin 10 mg/kg PO 3 times per week × 2 months
PLUS
Pyrazinamide 25mg/kg PO q24h for 2 months
OR
Pyrazinamide 35 mg/kg PO 3 times per week × 2 months
PLUS
Ethambutol 15mg/kg PO q24h for 2 months
Continuation Phase
Isoniazid 5mg/kg PO for 4-7 months
OR
Isoniazid 10 mg/kg PO 3 times per week × 4-7 months
PLUS
Rifampicin 10 mg/kg PO q24h for 4-7 months
OR
Rifampicin 10 mg/kg PO 3 times per week for 4-7 months
Adapted from Treatment of Tuberculosis: Guidelines.[7]
Borrelia burgdorferi
Preferred Regimen
Amoxicillin 500 mg q8h for 28 days
OR
Doxycycline 100 mg q12h for 28 days
OR
Cefuroxime 500 mg q12h for 28 days
Alternative Regimen
Azithromycin 500 mg PO q24h for 7–10 days
OR
Clarithromycin 500 mg PO q12h for 14–21 days
OR
Erythromycin 500 mg PO q6h for 14–21 days
Adapted from IDSA Guidelines: The Clinical Assessment, Treatment, and Prevention of Lyme Disease, Human Granulocytic Anaplasmosis, and Babesiosis: [8]
Treponema pallidum
Preferred Regimen
Penicillin G 2.4 MU IM single dose
Alternative Regimen
Doxycycline 100 mg PO q12h x 14 days
OR
Tetracycline 500 mg PO q6h x 14 days
OR
Ceftriaxone 1 g IM/IV q24h x 10 -14 days
Adapted from MMWR Recomm Rep. 2006;55(RR-11):1-94[9]
Tropheryma whipplei
Preferred Regimen
Penicillin G 2 MU IV q4h for 2 weeks
PLUS
Streptomycin 1 g IM/IV q24h for 2 weeks
FOLLOWED BY
Trimethoprim/Sulfamethoxazole 160mg/800mg PO q24h for 1 year
Alternative Regimen
Ceftriaxone 2 g IV q24h
FOLLOWED BY
Trimethoprim/Sulfamethoxazole 160mg/800mg PO q24h for 1 year
Adapted from N Engl J Med 2007; 356:55-66 [10]
Enterococcus spp.
Preferred Regimen
Ampicillin 2 g IV q6h
OR
Vancomycin 1 g IV q12h
Alternative Regimen
Ampicillin-Sulbactam 3 g IV q6h
OR
Linezolid 600 mg PO/IV q12h
Proteus mirabilis
Preferred Regimen
Ampicillin 2 g IV q6h
OR
Levofloxacin 500 mg IV/PO q24h
Alternative Regimen
Cefazolin 0.25–1 g IV/IM q6–8h
OR
TMP-SMX 8–10 mg/kg/day IV/PO q6–12h (TMP component)
OR
Gentamicin 3–5 mg/kg/day IV q6–8h

References

  1. Mathews CJ, Weston VC, Jones A, Field M, Coakley G (2010). "Bacterial septic arthritis in adults". Lancet. 375 (9717): 846–55. doi:10.1016/S0140-6736(09)61595-6. PMID 20206778.
  2. Shirtliff ME, Mader JT (2002). "Acute septic arthritis". Clin Microbiol Rev. 15 (4): 527–44. PMC 126863. PMID 12364368.
  3. Ariza, Javier; Bosilkovski, Mile; Cascio, Antonio; Colmenero, Juan D.; Corbel, Michael J.; Falagas, Matthew E.; Memish, Ziad A.; Roushan, Mohammad Reza Hasanjani; Rubinstein, Ethan; Sipsas, Nikolaos V.; Solera, Javier; Young, Edward J.; Pappas, Georgios (2007). "Perspectives for the Treatment of Brucellosis in the 21st Century: The Ioannina Recommendations". PLoS Medicine. 4 (12): e317. doi:10.1371/journal.pmed.0040317. ISSN 1549-1277.
  4. Franco MP, Mulder M, Gilman RH, Smits HL (2007). "Human brucellosis". Lancet Infect Dis. 7 (12): 775–86. doi:10.1016/S1473-3099(07)70286-4. PMID 18045560.
  5. Yousefi-Nooraie R, Mortaz-Hejri S, Mehrani M, Sadeghipour P (2012). "Antibiotics for treating human brucellosis". Cochrane Database Syst Rev. 10: CD007179. doi:10.1002/14651858.CD007179.pub2. PMID 23076931.
  6. Liu, C.; Bayer, A.; Cosgrove, S. E.; Daum, R. S.; Fridkin, S. K.; Gorwitz, R. J.; Kaplan, S. L.; Karchmer, A. W.; Levine, D. P.; Murray, B. E.; Rybak, M. J.; Talan, D. A.; Chambers, H. F. (2011). "Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children". Clinical Infectious Diseases. 52 (3): e18–e55. doi:10.1093/cid/ciq146. ISSN 1058-4838.
  7. Treatment of tuberculosis : guidelin. Geneva: World Health Organization. 2010. ISBN 978-92-4-154783-3.
  8. . doi:10.1086/522848. Missing or empty |title= (help)
  9. "http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5511a1.htm". Retrieved 19 May 2014. External link in |title= (help)
  10. Fenollar, Florence; Puéchal, Xavier; Raoult, Didier (2007). "Whipple's Disease". New England Journal of Medicine. 356 (1): 55–66. doi:10.1056/NEJMra062477. ISSN 0028-4793.